2.Endothelin antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster
摘要:
The methylendioxyphenyl group is present in a number of endothelin receptor antagonists thus far reported. By means of a Kohonen neural network we discovered with a benzothiadiazole a bioisosteric replacement instead. This group should be devoid of the negative metabolic interactions with cytochrome P450 ascribed to methylendioxyphenyl in vivo. The synthesis of a potent benzothiadiazole analogue EMD 122801 together with in vitro studies of different methylendioxyphenyl, benzothiadiazole and benzofurazan derivatives is described. (C) 1997 Elsevier Science Ltd. All rights reserved.
Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists
申请人:Merck Patent Gesellschaft mi beschraenkter Haftung
公开号:US06197800B1
公开(公告)日:2001-03-06
Novel compounds of the formula I
in which
R is
X is O or S,
and
R1, R2, R3, R4, R5 and R6 have the meaning indicated in patent claim 1,
or a tautomeric ring-closed form, and the (E) isomers and their salts
exhibit endothelin receptor-antagonistic properties.
2,1,3-benzothia(OXA)diazole derivatives having an endothelin receptor
申请人:Merck Patent Gesellschaft
公开号:US06017939A1
公开(公告)日:2000-01-25
The invention concerns compounds of formula (I), in which R is (i), (ii) or (iii); n is 0, 1 or 2; X means O or S; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have different meanings, or a cyclized tautomeric shape. The invention also concerns the (E) isomers and salts of these compounds which display endothelin receptor antagonistic properties. ##STR1##